Healthcare entity
Insilico Medicine is most often covered alongside Pharma.AI, which appears in 2 of these 3 stories. Coverage clusters in market-trends, which accounts for 2 of those 3, with the remainder spread across 1 other category. They are less corroborated than the beat average, carrying 2.7 original sources each against 3.8 for the same window.
Last mentioned: Jul 15, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Insilico Medicine is most often covered alongside Pharma.AI, which appears in 2 of these 3 stories. Coverage clusters in market-trends, which accounts for 2 of those 3, with the remainder spread across 1 other category. They are less corroborated than the beat average, carrying 2.7 original sources each against 3.8 for the same window. That works out to roughly 0.2 stories per week across a 132-day span. Their average consequence score of 7 runs above the beat's 6.1 for that window. Insilico Medicine appears in 3 tracked Healthcare stories published from March 6, 2026 through July 15, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 607 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Insilico Medicine. Shared-story counts are live from our verified record — not editorial picks.
Phase I Milestone
First human subject enrolled and dosed in the Phase I clinical trial.
AI Discovery
Insilico Medicine identifies ISM4808 using its Pharma.AI platform.
Out-Licensing
TaiGen Biotechnology secures rights for the clinical development of the candidate.
The strategic alliance between AI drug discovery firm Insilico Medicine and global CDMO Bora Pharmaceuticals seeks to merge generative AI with manufacturing at scale. With a potential value exceeding $2.5 billion, the partnership could accelerate drug development and strengthen supply chain resilience, directly impacting healthcare delivery and cost structures.
A breakthrough $2.5B collaboration between AI drug discoverer Insilico Medicine and CNS specialist SK Biopharmaceuticals aims to tackle devastating neuroimmune disorders that have long defied conventional drug development. By combining generative AI with established clinical expertise, the partnership could dramatically shorten timelines and deliver first‑in‑class therapies to patients with conditions like Alzheimer's, multiple sclerosis, and rare neuroinflammatory diseases.
Insilico Medicine and TaiGen have successfully enrolled and dosed the first human subject in a Phase I clinical trial for ISM4808, a novel drug candidate for Chronic Kidney Disease (CKD) anemia. The milestone validates the clinical transition of an AI-discovered molecule under a strategic out-licensing agreement.
Source: finanznachrichten.de · manilatimes.net
Insilico Medicine is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
